Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results
Naslov
Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results
Identifikator
/unibl/sci/idNaucniRad:25129
Tip
Pronađite slične unoseAcademic Article
Datum
Bibliografski citat
J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017
Početna stranica
10
Krajnja stranica
10
Je dio
RHEUMATOLOGY
1462-0324
Lista autora
Position: 16793 (33 views)